[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Zhongnan Hospital\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":626},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,28,0,25,[9,46,67,95,116,147,174,202,223,248,275,296,318,343,364,386,406,433,457,482,505,528,550,575,601],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":4,"eligibilityCriteria":16,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":28,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100627848","efficacy-and-safety-of-intrapulmonary-percussive-ventilation-in-patients-with-pulmonary-infection-receiving-invasive-mechanical-ventilation-100627848",false,"NCT07453966","Efficacy and Safety of Intrapulmonary Percussive Ventilation in Patients With Pulmonary Infection Receiving Invasive Mechanical Ventilation","Efficacy and Safety of Intrapulmonary Percussive Ventilation in Patients With Pulmonary Infection Receiving Invasive Mechanical Ventilation Assessed by Electrical Impedance Tomography: a Randomized Controlled Trial","Inclusion Criteria:\n\n1. age ≥ 18 years;\n2. Meeting the diagnostic criteria for pulmonary infection, defined as follows: meeting the diagnostic criteria for hospital-acquired pneumonia and ventilator-associated pneumonia as defined in the Chinese Guidelines for the Diagnosis and Treatment of Hospital-Acquired Pneumonia and Ventilator-Associated Pneumonia in Adults, or meeting the diagnostic criteria for community-acquired pneumonia as defined in the Chinese Guidelines for the Diagnosis and Treatment of Community-Acquired Pneumonia in Adults; radiographic evidence of new or progressive pulmonary infiltrates plus at least two clinical criteria, including fever or hypothermia, leukocytosis or leukopenia, purulent respiratory secretions, or worsening oxygenation.\n3. Oxygenation index (PaO₂\u002FFiO₂) ≤ 300;\n4. Currently receiving invasive mechanical ventilation and expected to require mechanical ventilation for ≥ 5 days;\n5. Written informed consent provided by the patient's family member or legally authorized representative.\n\nExclusion Criteria:\n\n1. Presence of severe hemodynamic instability (norepinephrine dose \\> 0.5 μg\u002Fkg\u002Fmin);\n2. Markedly elevated intracranial pressure (\\> 25 mmHg) or a condition requiring strict intracranial pressure control;\n3. Severe pulmonary bullae or untreated tension pneumothorax or undrained mediastinal emphysema;\n4. Active massive hemoptysis;\n5. Severe bronchospasm with inability to tolerate fluctuations in airway pressure;\n6. Unstable chest wall, flail chest, recent thoracic surgery, or severe thoracic spine injury;\n7. Receiving extracorporeal membrane oxygenation (ECMO);\n8. Pregnant or breastfeeding women;\n9. Inability to place the EIT chest belt (e.g., open thoracic surgical wounds or skin lesions at the belt placement site);\n10. Concurrent participation in another clinical trial.","ALL","18 Years",{"count":20,"type":21},96,"ESTIMATED","INTERVENTIONAL",[24],"NA","The goal of this clinical trial is to learn whether adding intrapulmonary percussion ventilation (IPV) to standard airway clearance treatment improves clinical outcomes in invasively mechanically ventilated patients with pulmonary infection. It will also evaluate the safety of IPV in this population and assess changes in lung ventilation using electrical impedance tomography (EIT).\n\nThe main questions it aims to answer are:\n\nDoes adding IPV shorten the duration of invasive mechanical ventilation compared with standard therapy alone? Does IPV improve regional and global lung ventilation? Does IPV improve clinical indicators, including oxygenation, lung mechanics, and pulmonary infection scores? Is IPV safe in mechanically ventilated patients with pulmonary infection?\n\nParticipants will:\n\nReceive either standard therapy alone or standard therapy plus IPV Undergo serial EIT monitoring at predefined time points Receive routine clinical assessments and ventilator parameter monitoring during ICU stay Be followed until successful weaning, discharge, or completion of hospitalization",[27],"Pneumonia",[27,29,30,31,32],"Intrapulmonary percussion ventilation","mechanical ventilation","electrical impedance tomography","pulmonary infection","RECRUITING","2026-05-19",{"date":36,"type":37},"2026-05-22","ACTUAL",{"date":39,"type":37},"2026-03-06",{"date":41,"type":21},"2027-05-01",{"name":43,"class":44},"Zhongnan Hospital","OTHER",1,{"id":47,"slug":48,"hasResults":12,"nctId":49,"briefTitle":50,"officialTitle":50,"acronym":4,"eligibilityCriteria":51,"healthyVolunteers":12,"sex":17,"minAge":52,"maxAge":4,"enrollmentInfo":53,"targetDuration":4,"studyType":55,"phases":4,"briefSummary":56,"conditions":57,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":59,"lastUpdatePostDateStruct":60,"startDateStruct":62,"completionDateStruct":64,"leadSponsor":66,"locationsCount":45},"100634437","the-multi-omics-analysis-of-lens-zonule-relaxation-in-the-pacg-pathogenesis-100634437","NCT07539675","The Multi-Omics Analysis of Lens Zonule Relaxation in The PACG Pathogenesis","Inclusion Criteria:\n\n* Clinically diagnosed with primary angle-closure glaucoma (PACG)\n* Aged ≥ 50 years, no gender restriction\n* Case Group A: Undergoing glaucoma surgery with intraoperatively confirmed significant zonular laxity\n* Case Group B: Undergoing glaucoma surgery with intraoperatively confirmed normal zonular morphology\n* Control group: age- and sex-matched with case groups; clinically diagnosed with age-related cataract; normal anterior chamber depth and angle; no history or signs of glaucoma; undergoing cataract surgery\n\nExclusion Criteria:\n\n* Secondary glaucoma\n* History of previous intraocular surgery\n* Systemic diseases that can cause abnormal ocular zonules\n* Other severe ocular diseases\n* Long-term use of medications affecting connective tissue metabolism","50 Years",{"count":54,"type":21},150,"OBSERVATIONAL","Compared with primary angle-closure glaucoma (PACG) patients without zonular laxity and the control group, there are differentially expressed molecules in PACG patients with zonular laxity, and a potential mechanistic network can be constructed therefrom.",[58],"Primary Angle-Closure Glaucoma","2026-04-13",{"date":61,"type":37},"2026-04-20",{"date":63,"type":37},"2025-10-01",{"date":65,"type":21},"2027-09-30",{"name":43,"class":44},{"id":68,"slug":69,"hasResults":12,"nctId":70,"briefTitle":71,"officialTitle":72,"acronym":4,"eligibilityCriteria":73,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":74,"enrollmentInfo":75,"targetDuration":4,"studyType":22,"phases":77,"briefSummary":79,"conditions":80,"keywords":82,"overallStatus":86,"whyStopped":4,"lastUpdateSubmitDate":87,"lastUpdatePostDateStruct":88,"startDateStruct":90,"completionDateStruct":92,"leadSponsor":94,"locationsCount":45},"100632613","phase-2-fuliri-plus-targeted-therapy-for-first-line-conversion-therapy-of-colorectal-cancer-liver-metastases-100632613","NCT07515963","FULIRI Plus Targeted Therapy for First-line Conversion Therapy of Colorectal Cancer Liver Metastases.","A Phase II Clinical Study of FULIRI Regimen Chemotherapy Combined With Targeted Therapy for First-line Conversion Treatment of Colorectal Cancer Liver Metastases.","Inclusion Criteria:\n\n\\- (1) Age 18-75 years; (2) Histologically confirmed colorectal adenocarcinoma; (3) Synchronous liver metastasis of colorectal cancer, or liver metastasis occurring after curative surgery for colorectal cancer, and no prior systemic anti-tumor treatment (including but not limited to systemic chemotherapy, molecular targeted therapy, immunotherapy, biological therapy, and other investigational drugs) after diagnosis of liver metastasis; (4) Liver metastasis deemed unresectable by MDT assessment, or potentially resectable but with a CRS score ≥3; (5) For patients who have received neoadjuvant or adjuvant therapy for colorectal cancer, the date of first diagnosis of liver metastasis must be at least 6 months after the last dose of neoadjuvant or adjuvant therapy; (6) At least one measurable target lesion on CT scan, assessable according to RECIST v1.1 criteria; (7) ECOG performance status 0-2; (8) Good organ function, without severe comorbidities of the heart, liver, lungs, kidneys, brain, etc.; (9) Blood routine: HGB ≥90 g\u002FL, WBC \\>3.5 × 10\\^9\u002FL (NEU ≥1.5 × 10\\^9\u002FL), PLT ≥90 × 10\\^9\u002FL; Liver function: ALT or AST ≤2.5 times the upper limit of normal (ULN); Bilirubin ≤1.5 × ULN; Renal function: serum creatinine ≤1.5 × ULN; (10) Female subjects of childbearing potential must have a negative serum pregnancy test within 7 days before starting the study medication and be willing to use a medically approved highly effective contraceptive method during the study and for 3 months after the last dose of study medication; male subjects with partners of childbearing potential must agree to use effective contraception during the study and for 3 months after the last dose of study medication.\n\n(11) The subject has given informed consent and signed the informed consent form, and is willing and able to comply with the planned visits, study treatment, laboratory tests, and other study procedures.\n\nExclusion Criteria:\n\n* (1) Pathological diagnosis reveals the presence of neuroendocrine tumor, squamous cell carcinoma, or adenosquamous carcinoma components; (2) Presence of conditions requiring emergency treatment, such as bowel obstruction, bowel perforation, or bleeding; (3) Presence of multiple metastases in sites other than the liver (excluding localized lung metastases (≤2) or localized retroperitoneal lymph node metastases, provided the investigator assesses that the patient has a chance of achieving NED status); (4) Patients with known microsatellite instability-high (MSI-H) or mismatch repair deficiency (dMMR) who are deemed suitable for immunotherapy with immune checkpoint inhibitors by the investigator; (5) Previous treatment with irinotecan; (6) Underweight (Body Mass Index \\[BMI\\] \\\u003C 18 kg\u002Fm2); (7) Concurrent or previous history of other malignancies besides cervical carcinoma in situ and basal cell carcinoma of the skin; (8) Concurrent severe infection or active pulmonary tuberculosis; (9) History of immunodeficiency, including HIV positive, or other acquired or congenital immunodeficiency diseases, or history of organ transplantation; (10) Patients with hepatitis B, if hepatitis B DNA exceeds 1000 copies\u002FmL, should be excluded; patients with hepatitis C, if hepatitis C RNA is positive, should be excluded; (11) Received surgery or other anti-tumor treatments (including chemotherapy, radiotherapy, investigational treatments, etc.) within 4 weeks prior to enrollment; (12) Concurrent severe gastrointestinal dysfunction (\\> Grade I according to NCI-CTCAE v5.0, such as intestinal inflammation or diarrhea); (13) Presence of conditions within the past 6 months that contraindicate targeted therapy, such as arterial embolism, severe bleeding, or bowel perforation (excluding bleeding caused by surgery); (14) Concurrent severe or uncontrolled systemic diseases, including but not limited to hypertension (systolic blood pressure consistently above 150 mmHg, diastolic blood pressure consistently above 95 mmHg), diabetes, heart disease, etc.; (15) Patients who cannot tolerate this study or who may be allergic to the medications used in this study; (16) Patients with cognitive impairment or co-existing severe mental disorders, who are judged by the investigator to have poor adherence to chemotherapy; or other situations deemed unsuitable for participation in clinical research by the investigator.","75 Years",{"count":76,"type":21},24,[78],"PHASE2","This study is a single-center, prospective, randomized, single-arm phase II clinical trial designed to evaluate the safety and efficacy of FULIRI chemotherapy regimen combined with targeted therapy (bevacizumab\u002Fcetuximab) as first-line conversion therapy for colorectal cancer with liver metastases. Eligible patients with colorectal cancer and liver metastases, after signing informed consent, received FULIRI chemotherapy combined with bevacizumab\u002Fcetuximab targeted therapy. Efficacy was assessed after every four treatment cycles, followed by multidisciplinary team (MDT) discussion regarding potential surgical resection, ablation, or stereotactic radiotherapy. The primary endpoint was the objective response rate (ORR), and secondary endpoints included: disease control rate (DCR), R0 resection rate of liver metastases, progression-free survival (PFS), 3-year\u002F5-year survival rates, and the incidence of acute toxicities of any grade and grades 3\u002F4.",[81],"Colo-rectal Cancer",[83,84,85],"Colorectal cancer","Liver metastasis","FULIRI","NOT_YET_RECRUITING","2026-03-30",{"date":89,"type":37},"2026-04-07",{"date":91,"type":21},"2026-06-01",{"date":93,"type":21},"2028-02-01",{"name":43,"class":44},{"id":96,"slug":97,"hasResults":12,"nctId":98,"briefTitle":99,"officialTitle":99,"acronym":4,"eligibilityCriteria":100,"healthyVolunteers":101,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":102,"targetDuration":4,"studyType":55,"phases":4,"briefSummary":104,"conditions":105,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":107,"lastUpdatePostDateStruct":108,"startDateStruct":110,"completionDateStruct":112,"leadSponsor":114,"locationsCount":115},"100628332","a-study-on-the-effect-of-medical-students-literature-reading-patterns-on-cognitive-load-and-academic-writing-ability-100628332","NCT07460258","A Study on the Effect of Medical Students' Literature Reading Patterns on Cognitive Load and Academic Writing Ability","Inclusion Criteria:\n\n* Students currently enrolled in our school's clinical medicine or related programs. Voluntarily participate and sign the informed consent form.\n\nExclusion Criteria:\n\n* Native English speakers or those with a background in translation. Previously, they have read the specific literature selected for this study.",true,{"count":103,"type":21},160,"Compare the effects of three English medical literature reading modes (original text reading, bilingual comparison, full translation) on medical students' accuracy in literature comprehension, perceived cognitive load, mastery of professional terminology, and academic writing ability; assess whether reliance on artificial intelligence translation triggers a 'terminology shortage' phenomenon.",[106],"Accuracy in Understanding the Core Content of English Medical Literature","2026-03-04",{"date":109,"type":37},"2026-03-10",{"date":111,"type":37},"2026-01-20",{"date":113,"type":21},"2026-06-15",{"name":43,"class":44},3,{"id":117,"slug":118,"hasResults":12,"nctId":119,"briefTitle":120,"officialTitle":120,"acronym":121,"eligibilityCriteria":122,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":123,"targetDuration":4,"studyType":22,"phases":125,"briefSummary":127,"conditions":128,"keywords":130,"overallStatus":86,"whyStopped":4,"lastUpdateSubmitDate":140,"lastUpdatePostDateStruct":141,"startDateStruct":143,"completionDateStruct":144,"leadSponsor":146,"locationsCount":45},"100625238","early-phase-1-an-open-label-single-arm-single-center-study-to-evaluate-the-diagnostic-efficacy-of-a-novel-pet-probe-68ga-sfb6-zn01-in-patients-with-malignant-tumors-100625238","NCT07420036","An Open-label, Single-arm, Single-center Study to Evaluate the Diagnostic Efficacy of a Novel PET Probe, 68Ga-SFB6-ZN01, in Patients With Malignant Tumors","SFB6-ZN01 PET","Inclusion Criteria:\n\n* Voluntary written informed consent.\n* Age ≥ 18 years, male or female.\n* Clinically suspected or pathologically confirmed malignant solid tumor, or suspicion of recurrence after treatment.\n* Eastern Cooperative Oncology Group performance status (ECOG PS) 0-1.\n* Life expectancy ≥ 6 months.\n* Female subjects of childbearing potential and male subjects with partners of childbearing potential must agree to use highly effective contraception from consent until 6 months after study agent administration.\n\nExclusion Criteria:\n\n* Administration of any radionuclide within a period less than 10 physical half-lives before study agent injection.\n* Concurrent participation in another interventional clinical trial involving an investigational drug or device.\n* Known hypersensitivity to 68Ga-SFB6-ZN01 or any of its excipients.\n* Inability to lie flat or remain still during PET\u002FCT acquisition, or any contraindication to PET\u002FCT.\n* Pregnancy or breastfeeding.\n* Any other condition that, in the opinion of the investigator, would make the subject unsuitable for participation.",{"count":124,"type":21},98,[126],"EARLY_PHASE1","This study is being done to test a new imaging agent called 68Ga-SFB6-ZN01, which helps visualize tumors using PET\u002FCT scans. The agent attaches to a protein called integrin αvβ6, which is found on the surface of many cancer cells but rarely on normal cells. A total of 98 adults who either have a confirmed cancer diagnosis, are strongly suspected of having cancer, or may have recurrent cancer after previous treatment will be enrolled. Each participant will receive a single injection of 68Ga-SFB6-ZN01 and undergo one PET\u002FCT scan within one week of joining the study. The main goals are: to see how safe the imaging agent is and whether it causes any side effects; to understand how the agent distributes in the body, and how much radiation exposure it gives; to determine how accurately 68Ga-SFB6-ZN01 PET\u002FCT can detect cancerous lesions and correctly stage the disease, using biopsy results or long-term follow-up (≥6 months) as the reference standard; to explore whether the PET signal intensity (e.g., SUVmax) correlates with the expression of integrin αvβ6 in the tumor tissue. No therapeutic treatment is given in this study. Participation involves one imaging visit and follow-up contact. The results will help determine whether this new tracer should be developed further for cancer imaging.",[129],"Neoplasms",[131,132,133,134,135,136,137,138,139],"68Ga-SFB6-ZN01","Integrin αvβ6","PET\u002FCT","Positron Emission Tomography","Diagnostic Accuracy","Sensitivity and Specificity","Biodistribution","Radiation Dosimetry","Solid Tumor","2026-02-28",{"date":142,"type":37},"2026-03-03",{"date":109,"type":21},{"date":145,"type":21},"2028-12-31",{"name":43,"class":44},{"id":148,"slug":149,"hasResults":12,"nctId":150,"briefTitle":151,"officialTitle":152,"acronym":4,"eligibilityCriteria":153,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":154,"enrollmentInfo":155,"targetDuration":4,"studyType":55,"phases":4,"briefSummary":157,"conditions":158,"keywords":162,"overallStatus":86,"whyStopped":4,"lastUpdateSubmitDate":167,"lastUpdatePostDateStruct":168,"startDateStruct":170,"completionDateStruct":172,"leadSponsor":173,"locationsCount":45},"100622617","evaluation-of-the-diagnostic-efficacy-of-a-v6fap-targeting-heterodimeric-probe-in-patients-with-malignant-solid-tumors-100622617","NCT07385950","Evaluation of the Diagnostic Efficacy of a αvβ6\u002FFAP-Targeting Heterodimeric Probe in Patients With Malignant Solid Tumors","Evaluation of Diagnostic Efficacy of a αvβ6\u002FFAP-Targeting Heterodimeric Probe in Patients With Malignant Solid Tumors: An Open-Label, Single-Arm, Single-Center Study","Inclusion Criteria:\n\n1. Voluntarily provide written informed consent.\n2. Age ≥ 18 years.\n3. Newly diagnosed with a clinically\u002Fradiologically suspected or pathologically confirmed malignant solid tumor, or with suspected recurrence after prior treatment.\n4. Eastern Cooperative Oncology Group Performance Status (ECOG PS) score of 0 or 1.\n5. Life expectancy \\> 6 months.\n6. Participants of childbearing potential and their partners must agree to use highly effective contraception for 6 months following the last dose of the investigational agent.\n\nExclusion Criteria:\n\n1. Prior radioisotope therapy within an interval less than 10 times the physical half-life of the respective radionuclide before study administration.\n2. Concurrent participation in any other interventional clinical trial.\n3. Known allergy or hypersensitivity to the investigational agent or any of its excipients.\n4. Inability to lie still for the duration of the PET scan or any condition contraindicating PET imaging.\n5. Pregnancy or lactation.\n6. Any other condition that, in the investigator's judgment, would compromise participant safety or study integrity.","90 Years",{"count":156,"type":21},100,"Malignant tumors pose a grave threat to human health and impose a substantial burden on society. Molecular imaging, which enables non-invasive, in vivo visualization of biological processes at the molecular level, is crucial for early diagnosis and treatment monitoring, thereby improving clinical management. Currently, molecular probes targeting fibroblast activation protein (FAP) and integrin αvβ6, such as ⁶⁸Ga-labeled FAPI and ⁶⁸Ga-Trivehexin, have shown promise in oncologic PET imaging, yet each has limitations.\n\nFAP is predominantly overexpressed in cancer-associated fibroblasts within the tumor stroma, with minimal expression in normal tissues. However, radiotracers like ⁶⁸Ga-FAPI often exhibit physiological uptake in normal organs (e.g., salivary glands, pancreas, uterus), leading to elevated background signals and potentially reduced diagnostic contrast. Conversely, integrin αvβ6 is primarily expressed on tumor cell surfaces and is upregulated in many malignancies. Nonetheless, probes like ⁶⁸Ga-Trivehexin suffer from high renal retention with slow clearance and notable physiological gastrointestinal uptake, resulting in suboptimal target-to-background ratios and compromised image quality.\n\nGiven the complementary expression profiles of FAP (stroma) and integrin αvβ6 (tumor cells), we hypothesize that a bispecific molecular probe capable of simultaneously engaging both targets could achieve superior tumor targeting through a synergistic \"dual-lock\" mechanism. This prospective exploratory clinical trial aims to evaluate the diagnostic efficacy and safety of a novel bispecific probe, named ⁶⁸Ga-B6FA-01, in patients with malignant solid tumors. The ultimate goal is to develop a superior imaging strategy for early and precise tumor diagnosis, treatment response assessment, and personalized therapeutic decision-making.",[159,160,161],"PET \u002F CT","Solid Tumors","Adult",[163,164,165,166],"integrin αVβ6","FAP","PET imaging","Diagnostic efficacy","2026-01-26",{"date":169,"type":37},"2026-02-04",{"date":171,"type":21},"2026-01-15",{"date":145,"type":21},{"name":43,"class":44},{"id":175,"slug":176,"hasResults":12,"nctId":177,"briefTitle":178,"officialTitle":179,"acronym":4,"eligibilityCriteria":180,"healthyVolunteers":12,"sex":181,"minAge":18,"maxAge":74,"enrollmentInfo":182,"targetDuration":4,"studyType":22,"phases":184,"briefSummary":185,"conditions":186,"keywords":190,"overallStatus":86,"whyStopped":4,"lastUpdateSubmitDate":196,"lastUpdatePostDateStruct":197,"startDateStruct":198,"completionDateStruct":200,"leadSponsor":201,"locationsCount":45},"100620877","phase-2-a-phase-ii-study-of-utidelone-with-toripalimab-in-advanced-cervical-cancer-100620877","NCT07363330","A Phase II Study of Utidelone With Toripalimab in Advanced Cervical Cancer","Utidelone Combined With Toripalimab in Patients With Pretreated Recurrent or Metastatic Cervical Cancers: a Single-Arm, Phase II Study","Inclusion Criteria:\n\n1. Informed Consent: Patients must voluntarily sign an informed consent form prior to any study-related procedures.\n2. Age: Aged ≥18 years and ≤75 years.\n3. Diagnosis: Histologically or cytologically confirmed recurrent or metastatic cervical carcinoma.\n4. Performance Status: With an Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2.\n5. Measurable Disease: With at least one measurable lesion as per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1.\n6. Prior Therapy:\n\n   * Patients must have received at least one line of standard systemic chemotherapy for recurrent\u002Fmetastatic disease, OR\n   * Patients with rapid disease progression (occurring within 6 months) during or after prior neoadjuvant or concurrent chemoradiotherapy.\n7. Treatment-Related Toxicity: Recovery from all toxicities related to prior anti-cancer therapies to ≤ Grade 1 (according to CTCAE v5.0). Patients with alopecia of any grade are eligible.\n8. Adequate Hematological Function (within 1 week prior to enrollment, per local laboratory reference ranges):\n\n   * White blood cell count (WBC) ≥ 2.5 × 10⁹\u002FL.\n   * Absolute neutrophil count (ANC) ≥ 1.5 × 10⁹\u002FL.\n   * Platelet count (PLT) ≥ 100 × 10⁹\u002FL.\n   * Hemoglobin (Hb) ≥ 9.0 g\u002FdL (transfusion or erythropoietin use is permitted to meet this criterion).\n9. Adequate Liver and Kidney Functions (within 1 week prior to enrollment, per local laboratory reference ranges):\n\n   * Total bilirubin (TBIL) ≤ 1.5 × the upper limit of normal (ULN).\n   * Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 2.5 × ULN (≤ 5 × ULN for patients with liver metastases).\n   * Calculated creatinine clearance (Ccr) ≥ 60 mL\u002Fmin.\n10. Contraception: Patients of childbearing potential must agree to use highly effective contraception during the study and for at least 90 days after the last dose of study treatment. A negative serum or urine pregnancy test is required for female patients of childbearing potential within 7 days prior to enrollment.\n11. Life Expectancy: Anticipated life expectancy of at least 12 weeks.\n12. Compliance: Patients must be able and willing to comply with the study protocol for treatment and follow-up.\n\nExclusion Criteria:\n\n1. Concurrent Malignancy: History of other active malignancies within the past 5 years, except for adequately treated basal cell carcinoma of the skin.\n2. Recent Anti-cancer Therapy: Any anti-cancer therapy (including chemotherapy, radical radiotherapy, hormonal therapy, biological therapy, or anti-cancer Chinese herbal medicine) within 4 weeks prior to the initiation of study treatment.\n3. Recent Major Surgery\u002FTrauma: Major surgical procedure (excluding diagnostic biopsy) or significant traumatic injury within 4 weeks prior to the first dose of study drug, or anticipation of the need for major surgery during the study period.\n4. Prior Neurotoxicity: History of ≥ Grade 3 neurological adverse reactions attributed to prior anti-microtubule therapy.\n5. Symptomatic CNS Metastases: Patients with symptomatic central nervous system (CNS) metastases.\n6. Pregnancy\u002FLactation: Women who are pregnant or breastfeeding.\n7. Hypersensitivity: Known or suspected hypersensitivity to any component of the study drugs or their excipients.\n8. Severe Comorbidities: Any uncontrolled or severe concurrent medical condition that, in the investigator's judgment, would preclude participation, including but not limited to:\n\n   * Severe cardiovascular or cerebrovascular disease.\n   * Uncontrolled diabetes mellitus or hypertension.\n   * Active severe infection.\n   * Active peptic ulcer disease.\n   * Uncontrolled psychiatric illness\u002Fdisorder.\n9. General Exclusion: Any other condition or circumstance that, in the opinion of the investigator, would compromise the patient's safety or compliance, or make the patient unsuitable for study participation.\n10. Contraindication to Steroids: Conditions for which corticosteroid use is contraindicated.","FEMALE",{"count":183,"type":21},32,[78],"This is a Phase II clinical trial to evaluate the safety and efficacy of Utidelone, a genetically engineered epothilone derivative, combined with Toripalimab, a PD-1 inhibitor, in patients with recurrent or metastatic cervical cancer who have progressed after standard treatments. The study will also assess the safety profile of this combination therapy. The primary objectives of this study include: (1) to determine the objective response rate (ORR), meaning whether the treatment can reduce the size of tumors or make them disappear, according to the RECIST 1.1 criteria; (2) to evaluate the safety of the treatment and document the side effects experienced by participants. This study is for individuals who: (1) are between 18 and 75 years old; (2) have a confirmed diagnosis of recurrent or metastatic cervical cancer; (3) have previously received at least one standard chemotherapy regimen that is no longer controlling the cancer; (4) are in generally good health, as determined by the study investigators. In this single-arm study, all participants will receive the same treatment: Utidelone will be administered by intravenous (IV) infusion over 1.5 hours, once a day for 5 consecutive days, in each 21-day treatment cycle; Toripalimab will be administered by IV infusion over 1.5 hours, once on Day 6 of each 21-day cycle. Participants may continue receiving the study drugs as long as they are benefiting from the treatment and side effects are manageable. Doctors will assess tumor size using imaging scans (like CT or MRI) every 6 weeks to monitor how the cancer responds to treatment. The study will take place at Zhongnan Hospital of Wuhan University and plans to include approximately 32 participants.",[187,188,189],"Cervical Cancer","Recurrent","Metastatic",[191,192,193,194,195],"cervical cancer","recurrent \u002F metastatic","Utidelone","Toripalimab","phase Ⅱ trial","2026-01-22",{"date":167,"type":37},{"date":199,"type":21},"2026-02-01",{"date":145,"type":21},{"name":43,"class":44},{"id":203,"slug":204,"hasResults":12,"nctId":205,"briefTitle":206,"officialTitle":206,"acronym":4,"eligibilityCriteria":207,"healthyVolunteers":101,"sex":17,"minAge":18,"maxAge":208,"enrollmentInfo":209,"targetDuration":4,"studyType":22,"phases":211,"briefSummary":212,"conditions":213,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":215,"lastUpdatePostDateStruct":216,"startDateStruct":218,"completionDateStruct":220,"leadSponsor":222,"locationsCount":45},"100538619","effects-of-acupoint-massage-around-eyes-on-ocular-biological-indexes-100538619","NCT06293196","Effects of Acupoint Massage Around Eyes on Ocular Biological Indexes","Inclusion Criteria:\n\n* healthy people of all ages\n\nExclusion Criteria:\n\n* presence of systemic diseases\n* history of other eye diseases, surgeries, and\u002For medications, as well as eye trauma\n* incomplete healing of the surgical site after eye surgery\n* consumption of coffee, tea, or vasodilators within 6 hours before the commencement of the test\n* exclusion of children, pregnant, and lactating women","80 Years",{"count":210,"type":21},55,[24],"This study aims to investigate whether the acupoint eye exercise could impact the biological parameters of the eye.",[214],"Investigating the Effects of Periocular Acupressure on Ocular Biological Indicators","2026-01-18",{"date":217,"type":37},"2026-01-21",{"date":219,"type":37},"2023-09-01",{"date":221,"type":21},"2026-06-30",{"name":43,"class":44},{"id":224,"slug":225,"hasResults":12,"nctId":226,"briefTitle":227,"officialTitle":227,"acronym":4,"eligibilityCriteria":228,"healthyVolunteers":12,"sex":17,"minAge":229,"maxAge":4,"enrollmentInfo":230,"targetDuration":4,"studyType":22,"phases":231,"briefSummary":232,"conditions":233,"keywords":236,"overallStatus":86,"whyStopped":4,"lastUpdateSubmitDate":240,"lastUpdatePostDateStruct":241,"startDateStruct":243,"completionDateStruct":245,"leadSponsor":247,"locationsCount":4},"100616950","study-on-the-efficacy-of-temporal-interference-stimulation-tis-for-parkinsons-disease-100616950","NCT07312279","Study on the Efficacy of Temporal Interference Stimulation (TIS) for Parkinson's Disease","Inclusion Criteria:\n\n1. Adult males or females aged 40 years or above;\n2. Diagnosed with idiopathic Parkinson's disease according to the UK Brain Bank Criteria, with onset after 40 years of age;\n3. Previous or current dopaminergic replacement therapy (e.g., levodopa) with good response; (4) Hoehn and Yahr (H\\&Y) stage 1.5-2.5;\n4. Ability to walk independently without assistive devices for at least 5 minutes;\n5. Absence of severe freezing of gait (FOG);\n6. Disease duration ≥2 years since diagnosis, with stable clinical condition and ability to comply with study assessments and interventions;\n7. Stable medication dosage for at least 4 weeks prior to the study;\n8. Hoehn and Yahr (H\\&Y) stage 1.5-2.5;\n9. Signed informed consent, with the participant or legal guardian capable of understanding and willing to participate in the study.\n\nExclusion Criteria:\n\n1. Presence of other neurological disorders that may interfere with the study\n2. Mild or greater cognitive impairment (MoCA score ≤23)\n3. Orthopedic or other health conditions that may affect gait or balance\n4. Contraindications to MRI scanning, such as claustrophobia\n5. History of antipsychotic, antidepressant, or other medications that may affect dopamine levels\n6. Other significant psychiatric history\n7. Contraindications including history of epilepsy, traumatic brain injury, or implanted metal devices in the brain or heart (e.g., stimulators, pacemakers)\n8. History of electroconvulsive therapy\n9. Concurrent participation in other gait- or balance-related intervention training\n10. Physician-diagnosed cardiovascular risk factors for exercise.","40 Years",{"count":76,"type":21},[24],"The primary objective of this clinical study is to evaluate the therapeutic efficacy of Temporal Interference Stimulation (TIS), a non-invasive deep brain stimulation technique, in patients with Parkinson's disease, and to further investigate its potential mechanisms of action. Although TIS offers lower stimulation intensity and precision compared to conventional Deep Brain Stimulation (DBS), it possesses the distinct advantage of being non-invasive. This study utilizes TIS to explore different stimulation targets analogous to those used in DBS for Parkinson's disease, thereby providing valuable insights for subsequent DBS surgical interventions. The findings will contribute preliminary exploratory evidence regarding the application of non-invasive deep brain stimulation technology in the treatment of Parkinson's disease.",[234,235],"Temporal Interference Stimulation (TIS)","Parkinson's Disease",[237,238,239],"TIS","Parkinson","UPDRS","2025-12-16",{"date":242,"type":37},"2025-12-31",{"date":244,"type":21},"2025-12-30",{"date":246,"type":21},"2026-12-31",{"name":43,"class":44},{"id":249,"slug":250,"hasResults":12,"nctId":251,"briefTitle":252,"officialTitle":253,"acronym":4,"eligibilityCriteria":254,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":154,"enrollmentInfo":255,"targetDuration":4,"studyType":22,"phases":257,"briefSummary":258,"conditions":259,"keywords":263,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":267,"lastUpdatePostDateStruct":268,"startDateStruct":270,"completionDateStruct":272,"leadSponsor":274,"locationsCount":45},"100616417","randomised-controlled-trial-of-artificial-intelligence-assisted-health-education-100616417","NCT07305337","Randomised Controlled Trial of Artificial Intelligence-assisted Health Education","The Impact of Artificial Intelligence-Assisted Health Education on Patients' Intention to Participate in Clinical Trials: A Cluster-Randomised Controlled Trial","Inclusion Criteria (1) Aged ≥18 years with clear consciousness; (2) Diagnosed with haematological malignancy meeting clinical treatment criteria (WHO criteria); (3) Capable of understanding health education content and possessing basic communication skills; (4) Willing to participate in this study and sign an informed consent form.\n\nExclusion Criteria\n\n(1) Patients with concomitant cognitive impairment, psychiatric disorders, or other conditions severely affecting comprehension; (2) Anticipated hospital stay of less than 3 days, rendering completion of the intervention unfeasible; (3) End-of-life palliative care; (4) Previous participation in other clinical trial education programmes.",{"count":256,"type":21},196,[24],"With the rapid advancement of biopharmaceutical technology, clinical trials have become the crucial bridge connecting new drugs from the laboratory to clinical application. Despite the increasing number of clinical trial projects being conducted, nearly all such projects face the common challenge of recruitment difficulties. Subject recruitment constitutes a pivotal stage in clinical trials; the ability to recruit a sufficient number of subjects meeting the trial requirements significantly impacts trial quality and also serves as a key factor influencing trial progress. Hematologic cancers constitute a highly heterogeneous group of malignant diseases originating in the haematopoietic organs and primarily affecting the haematopoietic system. They encompass acute and chronic leukaemias, malignant lymphomas, multiple myeloma, myelodysplastic syndromes, and related disorders. For patients facing treatment decisions, clinical trials represent not only a vital avenue for accessing cutting-edge therapies but also impose heightened demands on their capacity for informed decision-making. Conversational artificial intelligence (AI) based on large language models is rapidly advancing in health education and public health communication. Medical chatbots offer scalable and personalised advantages in delivering health information, promoting behavioural change, and enhancing patient engagement, providing a viable pathway for improving trial literacy and decision support. Accordingly, this study proposes to conduct a clinical trial literacy intervention using AI-powered chatbots among haematological malignancy patients. Through a randomised controlled trial (RCT), it aims to evaluate the impact of AI-assisted health education on patients' understanding of clinical trials and intention to participate. This research seeks to validate the application value of AI technology in health education and explore scalable AI-assisted health education intervention models.",[260,261,262],"Leukaemia","Multiple Myeloma (MM), Lymphoma, Large B-Cell, Diffuse (DLBCL), Lymphoma","Lymphoma",[260,264,262,265,266],"Multiple Myeloma","health education","artificial intelligence","2025-12-12",{"date":269,"type":37},"2025-12-26",{"date":271,"type":37},"2025-06-28",{"date":273,"type":21},"2026-08-30",{"name":43,"class":44},{"id":276,"slug":277,"hasResults":12,"nctId":278,"briefTitle":279,"officialTitle":280,"acronym":4,"eligibilityCriteria":281,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":74,"enrollmentInfo":282,"targetDuration":4,"studyType":22,"phases":284,"briefSummary":285,"conditions":286,"keywords":4,"overallStatus":86,"whyStopped":4,"lastUpdateSubmitDate":288,"lastUpdatePostDateStruct":289,"startDateStruct":291,"completionDateStruct":293,"leadSponsor":295,"locationsCount":45},"100615345","phase-2-radiotherapy-plus-capox-and-iparomlimab-and-tuvonralimab-ql1706-as-neoadjuvant-therapy-for-larc-100615345","NCT07291401","Radiotherapy Plus CAPOX, and Iparomlimab and Tuvonralimab (QL1706) as Neoadjuvant Therapy for LARC","Neoadjuvant Chemoradiotherapy Combined Cith Iparomlimab and Tuvonralimab (QL1706) Therapy for Locally Advanced Rectal Cancer：a Single-center, Prospective, Randomized, Phase II Clinical Trial","Inclusion Criteria:\n\n* (1) The patient is histologically diagnosed with rectal adenocarcinoma. (2) Age ≥18 years, \\\u003C75 years (3) Eastern Cooperative Oncology Group (ECOG) performance status score of 0-1 (4) AJCC stage of rectal cancer: cT3-4N0M0 or TanyN1-2M0 (5) The lower margin of the rectal tumor is ≤10cm from the anus. (6) At least one evaluable lesion based on RECIST 1.1 assessment. (7) Subjects should have adequate bone marrow and liver and kidney function reserves:\n\n  * Neutrophils ≥1.5×10⁹\u002FL, platelets ≥75×10⁹\u002FL, and hemoglobin ≥9 g\u002FdL\n\n    * Total bilirubin ≤1.5×Upper limit of normal (UNL); ASAT (SGOT) and\u002For ALAT (SGPT) ≤2.5×UNL (≤5×UNL if liver metastasis occurs); alkaline phosphatase ≤2.5×UNL (≤5×UNL if liver metastasis occurs, ≤10×UNL if bone metastasis occurs); LDH \\\u003C1500 U\u002FL\n\n      * Creatinine clearance (calculated according to the Cockcroft and Gault formula) \\>60 mL\u002Fmin or serum creatinine ≤1.5×UNL; (8) Voluntarily participate in this study and sign the informed consent form\n\nExclusion Criteria:\n\n* (1) Histopathological examination confirms the presence of other pathological types, such as squamous cell carcinoma, undifferentiated carcinoma, neuroendocrine carcinoma, etc.\n\n  (2) Pathological examination confirms microsatellite highly unstable dMMR\u002Fmsi-H (3) Presence of intestinal obstruction, intestinal perforation, bleeding, or other conditions requiring emergency surgery (4) History of pelvic radiotherapy (5) Comorbid malignant tumors (excluding cervical carcinoma in situ that has been cured for more than 2 years) (6) Receiving any other anti-tumor treatment (chemotherapy, radiotherapy, surgery, targeted therapy, immunotherapy) or participating in other new drug clinical trials within the past 4 weeks (7) Presence of the following cardiovascular and cerebrovascular diseases or risks:\n  1. Myocardial infarction, unstable angina, cerebrovascular accident, transient ischemic attack, acute or persistent myocardial ischemia, symptomatic heart failure (Class 2 or above as determined by the New York Heart Association functional classification) within 6 months prior to randomization, symptomatic or poorly controlled arrhythmia\n  2. 3 years prior to first use of the drug a. History of pulmonary embolism or other serious thromboembolism within the past month\n  3. Presence of aortic aneurysm, aortic dissection aneurysm, internal carotid artery stenosis or other major vascular diseases that may endanger life or require surgery within the past 6 months\n  4. History of myocarditis or cardiomyopathy or current examination suggests myocarditis\n  5. Left ventricular ejection fraction (LVEF) \\\u003C50%\n  6. Complete left bundle branch block, third-degree atrioventricular block (8) Active autoimmune disease requiring systemic treatment within 2 years prior to the start of study treatment, or an autoimmune disease that the investigator judges may relapse or is planned for treatment. The following are excluded:\n\n  \u003C!-- -->\n\n  1. Skin diseases that do not require systemic treatment (e.g., vitiligo, alopecia, psoriasis, or eczema)\n  2. Hypothyroidism caused by autoimmune thyroiditis that requires only stable doses of hormone replacement therapy\n  3. Type I diabetes that requires only stable doses of insulin replacement therapy\n  4. Childhood asthma that has completely resolved and requires no intervention in adulthood\n  5. The investigator determines that the disease will not recur without external triggering factors (9) Known or suspected active pulmonary tuberculosis (10) Subjects with active hepatitis B, inactive or asymptomatic hepatitis B virus (HBV) carriers (HBsAg positive) with HBV DNA \\> 500 IU\u002FmL or \\> 2500 copies\u002FmL), and subjects with active hepatitis C should be excluded. Inactive or asymptomatic carriers of hepatitis B who are treated and stable and meet the criteria of HBV DNA ≤500 IU\u002FmL or ≤2500 copies\u002FmL are eligible for enrollment. Subjects with cured hepatitis C who are HCVAb positive and HCV RNA negative are eligible for enrollment. (11) Subjects who require systemic treatment with glucocorticoids (\\>10 mg\u002Fday prednisone or equivalent dose) or other immunosuppressive drugs within 14 days prior to randomization. The following are exceptions:\n\n  a. Inhaled, ophthalmic, or topical corticosteroids are permitted if there is no active autoimmune disease.\n\n  b. Corticosteroids are used as a pretreatment for infusion-related reactions or allergic reactions (e.g., medication before CT scans).\n\n  (12) Pregnant or lactating women (13) Patients with currently uncontrolled comorbidities, such as decompensated cirrhosis, nephrotic syndrome, uncontrolled hyperglycemia, uncontrolled metabolic disorders, severe active peptic ulcer disease or gastritis, severe bleeding tendency, or coagulation disorders.\n\n  (14) Patients with known allergies to any component of the study drug (oxaliplatin, capecitabine, QL1706); a history of severe allergic reactions to other monoclonal or bispecific antibodies; or known allergies to multiple substances or severe allergic diseases.\n\n  (15) Patients who have received a live vaccine within 30 days prior to randomization or who plan to receive a live vaccine during the study period.\n\n  (16) Patients with cognitive impairment or severe comorbid mental disorders, or those deemed by the investigator to have poor chemotherapy adherence; or other cases deemed unsuitable for participation in clinical trials by the investigator.",{"count":283,"type":21},108,[78],"This study is a single-center, prospective, randomized, double-arm, Phase II clinical trial designed to evaluate the efficacy of radiotherapy combined with CAPOX, and Iparomlimab and Tuvonralimab (QL1706) as neoadjuvant therapy for locally advanced rectal cancer. Additionally, the study seeks to explore the relationship between biomarkers in blood and tumor tissue and treatment efficacy.\n\nEligible participants (locally advanced rectal cancer) were randomly assigned in a 1:1 ratio to two groups.\n\nParticipants will:\n\nGroup A patients received radiotherapy, chemotherapy, and immunotherapy. During the first week of radiotherapy, they received one cycle of CAPOX concurrent chemoradiotherapy. Two weeks after the completion of radiotherapy, they continued with four cycles of CAPOX combined with QL1706 immunotherapy.\n\nGroup B patients received radiotherapy and chemotherapy. After completing the concurrent radiotherapy and chemotherapy, they rested for 2-3 weeks before completing 3 cycles of CAPOX consolidation chemotherapy.\n\nTwo to three weeks after the completion of neoadjuvant therapy in groups A and B, the efficacy was evaluated, and a decision was made on whether to proceed with surgery or watchful waiting based on the efficacy.",[287],"Rectal Cancer Patients","2025-12-05",{"date":290,"type":37},"2025-12-18",{"date":292,"type":21},"2026-01-01",{"date":294,"type":21},"2029-01-01",{"name":43,"class":44},{"id":297,"slug":298,"hasResults":12,"nctId":299,"briefTitle":300,"officialTitle":301,"acronym":4,"eligibilityCriteria":302,"healthyVolunteers":101,"sex":181,"minAge":303,"maxAge":304,"enrollmentInfo":305,"targetDuration":4,"studyType":55,"phases":4,"briefSummary":307,"conditions":308,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":310,"lastUpdatePostDateStruct":311,"startDateStruct":313,"completionDateStruct":315,"leadSponsor":317,"locationsCount":45},"100487883","the-effect-of-eyeliner-on-tear-composition-tear-secretion-and-tear-film-stability-100487883","NCT05632887","The Effect of Eyeliner on Tear Composition, Tear Secretion and Tear Film Stability.","The Effect of Eyeliner on Tear Composition, Tear Secretion and Tear Film Stability：a Prospective Cohort Study.","Inclusion Criteria:\n\n* People aged 20-35 who use eyeliner or do not use eyeliner .\n* People who use eyeliner have used it for ≥ 1 year; Frequency ≥ 3 times\u002Fweek.\n\nExclusion Criteria:\n\n* Other serious systemic diseases.\n* Other systemic diseases related to ocular surface, such as rheumatoid arthritis, systemic lupus erythematosus, Sjogren's syndrome and other immune system diseases or other eye diseases, history of eye surgery and trauma.\n* Lactating women or pregnant women.\n* Use electronic products for more than 4 hours every day.\n* Patients with circadian rhythm disorder.\n* People with radiation exposure history.\n* Non permanent residents in Wuhan.","20 Years","35 Years",{"count":306,"type":21},80,"Eyeliner is one of the most common eye cosmetics. The main ingredients are titanium oxide, pigment, grease and preservative. The user will apply the eyeliner to the eyelid and eyelash. With the blinking again and again, the components of the eyeliner may enter the tear film and continue to act on the eye surface. Therefore, the investigators suspect that the use of eyeliner may be an important factor leading to dry eye disease. In order to explore the relationship between the use of eyeliner and dry eye disease, the investigators plan to collect eye surface characteristic data of the two groups of people who use eyeliner and who do not use it.Then use Raman analysis to explore whether the use of eyeliner will lead to changes in tear composition.The investigators intend to analyze the difference of tear composition between the two groups to understand the relationship between the change of tear composition and tear film stability.So that the investigators can identify the risk factors of dry eye disease, and provide basis for prevention and early treatment.",[309],"Dry Eye","2025-09-23",{"date":312,"type":37},"2025-09-29",{"date":314,"type":37},"2022-11-20",{"date":316,"type":21},"2026-09-30",{"name":43,"class":44},{"id":319,"slug":320,"hasResults":12,"nctId":321,"briefTitle":322,"officialTitle":323,"acronym":4,"eligibilityCriteria":324,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":74,"enrollmentInfo":325,"targetDuration":4,"studyType":22,"phases":327,"briefSummary":329,"conditions":330,"keywords":332,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":335,"lastUpdatePostDateStruct":336,"startDateStruct":338,"completionDateStruct":340,"leadSponsor":342,"locationsCount":45},"100602248","phase-1-high---dose-vitamin-c-infusion-regimen-based-on-pharmacokinetic-characteristics-for-patients-with-advanced-malignant-solid-tumors-100602248","NCT07121036","High - Dose Vitamin C Infusion Regimen Based on Pharmacokinetic Characteristics for Patients With Advanced Malignant Solid Tumors","Phase I Clinical Study of a New High - Dose Vitamin C Infusion Regimen Based on Pharmacokinetic Characteristics in Combination With Standard Systemic Therapy for Patients With Advanced Malignant Solid Tumors","Inclusion Criteria:\n\n* 1\\. Aged 18 - 75 years old, regardless of gender. 2. The subject voluntarily participates, gives full informed consent, signs a written informed consent form, and has good compliance.\n\n  3\\. Histologically or cytologically pathologically diagnosed as advanced or metastatic malignant solid tumor.\n\n  4\\. Physical function status: Eastern Cooperative Oncology Group (ECOG) performance status 0 - 1.\n\n  5\\. The patient must have at least one measurable lesion (RECIST 1.1). 6. Sufficient bone marrow, liver, kidney, and heart function were recorded within 7 days before enrollment, and the patient is suitable for routine chemotherapy indicated clinically according to normal care standards.\n\n  7\\. No history of calcium oxalate kidney stones. 8. Expected survival ≥ 12 weeks. 9. Pathological immunohistochemistry requires a negative catalase result. 10. Patients who are undergoing systemic anti - tumor treatment and have disease progression can also enter the protocol, continue the same treatment or start a different chemotherapy regimen without interruption.\n\nExclusion Criteria:\n\n* 1\\. Lack of pathological diagnosis of malignant solid tumor. 2. The patient currently has central nervous system (CNS) metastasis or a history of brain metastasis.\n\n  3\\. Severe gastrointestinal diseases, including active bleeding. 4. Patients with severe or uncontrolled infections, heart or nervous system diseases.\n\n  5\\. Major surgery within 4 weeks or local radiotherapy within 7 days before the administration of the study drug.\n\n  6\\. Dementia or severe mental status changes that prevent obtaining informed consent.\n\n  7\\. Women of childbearing potential must use an acceptable contraceptive method during the study and must undergo a pregnancy test within 7 days after the first chemotherapy.\n\n  8\\. The patient currently has poorly controlled diabetes (fasting blood glucose (FBG) \\> 10 mmol\u002FL).\n\n  9\\. Glucose - 6 - phosphate dehydrogenase (G6PD) deficiency or hereditary spherocytosis.\n\n  10\\. Active pulmonary tuberculosis (TB), patients who are undergoing anti - tuberculosis treatment or have received anti - tuberculosis treatment within 1 year before the first drug administration; patients with positive human immunodeficiency virus (HIV) antibodies; or patients with syphilis infection.\n\n  11\\. Active viral hepatitis. If HBsAg (+) and\u002For HBcAb (+), HBV DNA must be \\\u003C 500 IU\u002FmL, and during the study, the patient must continue the original anti - HBV treatment throughout the process or start using entecavir or tenofovir throughout the process. Patients with positive hepatitis C virus (HCV) ribonucleic acid (RNA) must receive antiviral treatment according to local standard treatment guidelines and have liver function within Grade 1 elevation of NCI - CTCAE Version 5.0.\n\n  12\\. Any abnormal laboratory values or medical conditions that, in the judgment of the investigator, make the patient unfit for the study.",{"count":326,"type":21},18,[328],"PHASE1","Vitamin C is an essential water - soluble vitamin for the human body. It plays an important role in various physiological processes as an antioxidant and cofactor for multiple enzymes. Most vertebrates can synthesize vitamin C by themselves, but humans can only obtain it from the diet due to inactivating mutations in the synthesis enzyme gene. The incidence of severe malnutrition in tumor patients is 58.2%, and they often have insufficient intake. Vitamin C can be used for the prevention and treatment of various diseases, including vitamin C deficiency, iron - deficiency anemia, atherosclerosis, and COVID - 19. Its role in anti - tumor treatment was first proposed by Cameron E and Pauling LN in the 1970s. However, it was not verified in a subsequent randomized controlled study at the Mayo Clinic, and this treatment has been controversial ever since. Until subsequent studies found that this difference may be due to different administration routes. Oral administration is limited by absorption, transportation, and metabolism. Even at the maximum tolerated dose, the plasma drug concentration is always \\\u003C 250 μmol\u002FL, while intravenous injection can safely reach a pharmacological plasma concentration of 25 - 30 mmol\u002FL, which is the key to exerting the anti - tumor effect. Therefore, intravenous injection of high - dose vitamin C (HDVC) as an emerging anti - tumor therapy has received renewed attention. A series of clinical studies have confirmed that a dose of 75 - 100 g\u002Fday (1.5 - 2.2 g\u002Fkg) is safe. Most pre - clinical experiments suggest that HDVC can inhibit the development or metastasis of tumors, significantly improve the survival rate of experimental animals, and prolong their survival time. It also has a synergistic or sensitizing effect on chemotherapy, radiotherapy, and targeted therapy. However, the number of clinical trials with positive results is very limited. Only a small number of studies have reported trends of increased disease control and objective response rates. For example, when combined with gemcitabine in the treatment of pancreatic cancer, the overall survival (OS) and progression - free survival (PFS) of patients were prolonged (21.7 months vs. 11.1 months; 13.7 months vs. 4.6 months). Currently, all clinical trials lack standardization and normativity in efficacy detection, and the repeatability of the experiments is poor. This has led to a situation where pre - clinical research shows good results, but clinical translation is very difficult. This may be closely related to the pharmacokinetic characteristics of vitamin C: a short half - life of only 30 minutes, high lability, first - order kinetic elimination, and rapid excretion through the kidneys. It is easily metabolized by the body's antioxidant system (especially reduced glutathione). After the infusion stops, the plasma vitamin C concentration drops rapidly, resulting in insufficient duration of the drug peak concentration or effective concentration to kill tumor cells in the body. Therefore, ensuring sufficient blood drug concentration, prolonging the duration of the effective concentration, and inhibiting the metabolism of antioxidants may improve the therapeutic effect of HDVC. This study attempts to summarize the clinical synergistic strategies of HDVC from existing clinical trials and explore a better HDVC treatment regimen. Based on comprehensive clinical research, we take patients with advanced malignant solid tumors receiving systemic anti - tumor treatment as the research objects. While patients are undergoing systemic anti - tumor treatment, HDVC treatment is combined. Three cohorts are designed: 0.5 g\u002Fkg once a day; 0.5 g\u002Fkg twice a day; 0.75 g\u002Fkg twice a day. All are intravenously dripped continuously for 5 - 7 days during the first cycle of standard systemic anti - tumor therapy, and the blood concentration of vitamin C is detected daily. The main objectives of this study are to study the pharmacokinetic characteristics of different high - dose vitamin C intravenous drip regimens in patients with advanced solid tumors, evaluate whether twice - daily administration can increase the blood concentration of vitamin C, and explore the appropriate regimen for combining high - dose vitamin C intravenous drip with standard systemic therapy in treating patients with advanced malignant solid tumors, providing ideas and a basis for the standardized clinical application of HDVC in the future.",[331],"Vitamin C",[333,334],"High - dose Vitamin C","cancer","2025-08-06",{"date":337,"type":37},"2025-08-13",{"date":339,"type":37},"2025-03-30",{"date":341,"type":21},"2027-12-31",{"name":43,"class":44},{"id":344,"slug":345,"hasResults":12,"nctId":346,"briefTitle":347,"officialTitle":348,"acronym":4,"eligibilityCriteria":349,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":154,"enrollmentInfo":350,"targetDuration":4,"studyType":22,"phases":352,"briefSummary":353,"conditions":354,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":357,"lastUpdatePostDateStruct":358,"startDateStruct":360,"completionDateStruct":362,"leadSponsor":363,"locationsCount":45},"100458923","cxcr4-targeted-petct-imaging-in-hematological-malignancies-100458923","NCT05255926","CXCR4-targeted PET\u002FCT Imaging in Hematological Malignancies","An Exploratory, Open-Label, Single Center Study of CXCR4-targeted PET\u002FCT Imaging for Evaluation of Hematological Malignancies","Inclusion Criteria:\n\n1. Volunteer to participate and sign an informed consent form;\n2. 18 ≤ Age ≤ 90 years;\n3. Patients with highly suspected, or newly diagnosed, or relapsed hematological malignancies;\n4. Willing and able to follow schedule visits, treatment plans and laboratory tests.\n\nExclusion Criteria:\n\n1. pregnancy or breastfeeding;\n2. Allergic to CXCR4-targeted tracers or excipients;\n3. Fasting blood glucose level exceeded 11.0 mmol\u002FL prior to injection of 18F-FDG;\n4. Those who cannot complete PET\u002FCT scan, including inability to keep supine, claustrophobia, radiation phobia, etc.;\n5. Researchers think it is inappropriate to participate in this clinical trial for patients with poor compliance or other unsuitable factors.",{"count":351,"type":21},300,[24],"Hematological malignancies continue to pose significant clinical challenges due to their high incidence, heterogeneous biology, and substantial mortality. Although 18F-FDG PET\u002FCT remains the most commonly used molecular imaging modality, its limited specificity can result in false-positive or false-negative findings, especially in indolent or low-metabolism subtypes, thereby hampering accurate diagnosis, staging, and therapeutic evaluation. C-X-C chemokine receptor type 4 (CXCR4) is frequently overexpressed in a broad spectrum of hematologic malignancies and correlates with aggressive disease and unfavorable outcomes. CXCR4-targeted molecular imaging using \\^68Ga-pentixafor PET\u002FCT has shown promise for improved disease characterization. This prospective study aims to systematically compare 68Ga-pentixafor PET\u002FCT with 18F-FDG PET\u002FCT in terms of diagnostic performance, staging accuracy, risk stratification, and prognostic relevance in patients with hematological malignancies. Furthermore, the study will incorporate artificial intelligence-based image analysis to enhance lesion detection, automate quantitative assessments, and support personalized clinical decision-making.",[355,133,356],"CXCR4","Hematological Malignancy","2025-06-22",{"date":359,"type":37},"2025-06-26",{"date":361,"type":37},"2022-03-01",{"date":246,"type":21},{"name":43,"class":44},{"id":365,"slug":366,"hasResults":12,"nctId":367,"briefTitle":368,"officialTitle":369,"acronym":4,"eligibilityCriteria":370,"healthyVolunteers":101,"sex":17,"minAge":18,"maxAge":371,"enrollmentInfo":372,"targetDuration":4,"studyType":22,"phases":374,"briefSummary":375,"conditions":376,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":379,"lastUpdatePostDateStruct":380,"startDateStruct":382,"completionDateStruct":384,"leadSponsor":385,"locationsCount":45},"100441881","68ga-fapi-petct-in-malignant-tumors-100441881","NCT05034146","68Ga-FAPI PET\u002FCT in Malignant Tumors","The Diagnostic Efficiency of 68Ga-FAPI PET\u002FCT in Malignant Tumors","Inclusion Criteria:\n\nVolunteering to participate in clinical trial and sign an informed consent form Patients with suspected or confirmed malignant tumor\n\nExclusion Criteria:\n\nFemale patients plan to become pregnant within 6 months Pregnant and lactating women Patients are allergic to multiple drugs including test drug Patients have participated in other clinical trials in the past one month","88 Years",{"count":373,"type":21},500,[24],"Fibroblast-activation protein (FAP) is a type Ⅱ transmembrane serine protease and is overexpressed in cancer-associated fibroblasts (CAFs). CAFs are the predominant component in the stroma of epithelial neoplasms. FAP can be detected in various of malignant neoplasms and is associated to tumor cell migration, invasion, and angiogenesis. Recently, a novel molecular probe, gallium 68-labelled FAP inhibitor (68Ga-FAPI), has been developed and used for visualization of tumor stroma by targeting FAP. Recent studies show favorable diagnosis efficiency in a variety of tumors, especially in gastrointestinal cancer, but the previous studies were all small-sample data or case reports. Therefore, further large-size research is necessary to confirm the advantages of 68Ga-FAPI in various of malignant tumors.",[377,133,378],"Fibroblast Activation Protein Inhibitor","Malignant Neoplasm","2025-05-31",{"date":381,"type":37},"2025-06-05",{"date":383,"type":37},"2021-02-23",{"date":242,"type":21},{"name":43,"class":44},{"id":387,"slug":388,"hasResults":12,"nctId":389,"briefTitle":390,"officialTitle":390,"acronym":391,"eligibilityCriteria":392,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":393,"enrollmentInfo":394,"targetDuration":4,"studyType":55,"phases":4,"briefSummary":395,"conditions":396,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":399,"lastUpdatePostDateStruct":400,"startDateStruct":402,"completionDateStruct":404,"leadSponsor":405,"locationsCount":45},"100441609","exploring-the-application-value-of-pet-molecular-imaging-targeting-fap-in-oral-squamous-cell-carcinoma-100441609","NCT05030597","Exploring the Application Value of PET Molecular Imaging Targeting FAP in Oral Squamous Cell Carcinoma","FAPI-OSCC","Inclusion Criteria:\n\n1. Voluntary participation with signed informed consent;\n2. Aged 18\\~70 years;\n3. Clinically highly suspected oral cancer and recurrence after treatment (Newly diagnosed patients: Scheduled for surgery or neoadjuvant therapy followed by surgery);\n4. Ability to complete baseline and follow-up PET\u002FCT (Follow-up FAPI PET\u002FCT applies only to locally advanced patients undergoing neoadjuvant therapy.).\n\nExclusion Criteria:\n\n1. Pregnant or breastfeeding women, or women planning pregnancy during the trial period;\n2. Known hypersensitivity to FAPI, FDG, or their components, or history of severe allergic reactions;\n3. People with poor general condition, their heart, lung, liver, kidney and other important organ functions cannot tolerate surgery;\n4. Before the injection of 18F-FDG, the fasting blood glucose level exceeded 11.0 mmol\u002FL;\n5. Claustrophobia or inability to tolerate PET\u002FCT imaging (Those who cannot tolerate lying supine for 15\\~30 minutes.);\n6. Participation in another interventional clinical trial within 30 days prior to enrollment, or planned participation during this study.","70 Years",{"count":156,"type":21},"In this prospective study, the investigators will use integrated PET\u002FCT with the agent 68Ga-FAPI and conventional imaging agent 18F-FDG to explore the application value of FAP-targeted molecular imaging in the diagnosis and staging for oral cancer. This study also aims to explore the application value of FAPI imaging in evaluating treatment response for oral cancer.",[133,397,398],"FAPI","Oral Cancer","2025-05-21",{"date":401,"type":37},"2025-05-28",{"date":403,"type":37},"2021-09-15",{"date":242,"type":21},{"name":43,"class":44},{"id":407,"slug":408,"hasResults":12,"nctId":409,"briefTitle":410,"officialTitle":411,"acronym":4,"eligibilityCriteria":412,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":413,"enrollmentInfo":414,"targetDuration":4,"studyType":55,"phases":4,"briefSummary":416,"conditions":417,"keywords":420,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":426,"lastUpdatePostDateStruct":427,"startDateStruct":429,"completionDateStruct":431,"leadSponsor":432,"locationsCount":45},"100503462","integrin-v6-targeted-pet-in-malignant-tumors-100503462","NCT05835570","Integrin αvβ6-targeted PET in Malignant Tumors","A Single-arm, Open-label, Single-center Clinical Study to the Evaluation of Integrin αvβ6-targeted Positron Emission Tomography (PET) for Malignant Tumors","Inclusion Criteria:\n\n* Participants with newly diagnosed malignant tumor confirmed by pathology or suspected lung cancer;\n* Age ≥18 years, regardless of gender;\n* No prior anti-tumor therapy (e.g., chemotherapy, radiotherapy, targeted therapy, or immunotherapy) before PET\u002FCT;\n* Eastern Cooperative Oncology Group Performance Status (ECOG PS) score of 0-1;\n* Female subjects of reproductive age, male subjects and their partners agree to use reliable contraceptive measures (e.g., abstinence, birth control pills, injectable contraceptives, or subcutaneous contraceptive implants) until 6 months after the completion of the study;\n* Participants should voluntarily consent to the clinical trial, and have the ability to understand and sign an informed consent form.\n\nExclusion Criteria:\n\n* Known allergy to injection or its excipients;\n* Severe liver or renal dysfunction;\n* Claustrophobia or other psychiatric disorders;\n* History of other malignant tumors;\n* Participation in another clinical trial within 30 days prior to PET\u002FCT scan;\n* Pregnant or breastfeeding women;\n* Refusal to participate or request for withdrawing from the clinical study;\n* Other conditions deemed unsuitable for inclusion by investigator.","85 Years",{"count":415,"type":21},200,"Malignant tumors are a significant health threat with high incidence and mortality rates, and molecular imaging is crucial for early diagnosis, staging, prognosis evaluation, and therapeutic efficacy assessment. 18F-FDG PET imaging is widely used, but has limitations. Integrin αvβ6 is a promising target for tumor-targeted imaging, as it is only expressed in cancerous or reconstructed epithelial cells. A new PET probe, 68Ga-Trivehexin, targeting integrin αvβ6 has been developed with better affinity and selectivity than previous probes. Clinical data supports its safety and metabolic stability, and future research will explore its diagnostic and staging value in different types of tumors, providing a new and precise evaluation method for malignant tumors.",[378,133,418,419],"Non-Small Cell Lung Cancer","Breast Cancer, Metastatic",[421,422,423,424,425],"Non-small cell lung cancer","Breast cancer","Integrin-αvβ6","[68Ga]Ga-Trivehexin","Malignant tumors","2025-04-27",{"date":428,"type":37},"2025-04-30",{"date":430,"type":37},"2023-01-01",{"date":244,"type":21},{"name":43,"class":44},{"id":434,"slug":435,"hasResults":12,"nctId":436,"briefTitle":437,"officialTitle":438,"acronym":4,"eligibilityCriteria":439,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":440,"targetDuration":4,"studyType":22,"phases":441,"briefSummary":442,"conditions":443,"keywords":446,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":449,"lastUpdatePostDateStruct":450,"startDateStruct":452,"completionDateStruct":454,"leadSponsor":456,"locationsCount":45},"100582084","effect-of-adding-electroacupuncture-to-anti-cancer-therapy-induced-peripheral-neuropathy-100582084","NCT06858709","Effect of Adding Electroacupuncture to Anti-cancer Therapy-induced Peripheral Neuropathy","Effect of Adding Electroacupuncture Combined With Standard Anti Chemotherapy-induced Peripheral Neuropathy Drugs to Anti-cancer Therapy-induced Peripheral Neuropathy: a Randomized Multicentered Clinical Trial.","Inclusion Criteria:\n\n* 18 years of age or older, of any nationality.\n* Patients diagnosed with malignant tumor.\n* Eligible patients will report altered sensations and\u002For pain and\u002For other neurological symptoms, with a grade between 2-3 for chemotherapy-induced peripheral neuropathy on the National Cancer Institute (NCI) Common Toxicity Criteria for Adverse Events-version 5.0 (NCI-CTCAE.v-5.0).\n* Predicted life expectancy of ≥3 months.\n* Intact skin without any breaches or purulent discharge.\n* Written informed consent by the patient before enrolment Patients must be able to comply with the study protocol, which includes attending the treatment sessions on time and completing the study questionnaires in accordance with the study protocol.\n\nExclusion Criteria:\n\n* History of pre-existing peripheral neuropathy before chemotherapy, including alcoholism, vitamin B deficiency, diabetes, HIV, congenital neuropathy, and toxic neuropathy.\n* Patients with skin damage, pus or scar at the acupuncture stimulation area.\n* Patients who are pregnant or breastfeeding.\n* Significant mental conditions.\n* Patients not fulfilling the inclusion criteria.\n* Patients receiving other acupuncture treatments during the trial.",{"count":54,"type":21},[24],"This study is being done to evaluate the potential benefits of using electroacupuncture to reduce the severity of chemotherapy-induced peripheral neuropathy for patients with peripheral neuropathy after chemotherapy.",[444,445],"Chemotherapy-induced Peripheral Neuropathy (CIPN)","Cancer",[447,448],"Chemotherapy-induced peripheral neuropathy (CIPN)","electroacupuncture treatment","2025-04-15",{"date":451,"type":37},"2025-04-20",{"date":453,"type":37},"2025-03-20",{"date":455,"type":21},"2027-03-30",{"name":43,"class":44},{"id":458,"slug":459,"hasResults":12,"nctId":460,"briefTitle":461,"officialTitle":462,"acronym":463,"eligibilityCriteria":464,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":154,"enrollmentInfo":465,"targetDuration":4,"studyType":55,"phases":4,"briefSummary":466,"conditions":467,"keywords":470,"overallStatus":86,"whyStopped":4,"lastUpdateSubmitDate":475,"lastUpdatePostDateStruct":476,"startDateStruct":478,"completionDateStruct":480,"leadSponsor":481,"locationsCount":45},"100586520","granzyme-b-targeted-pet-imaging-monitoring-tumor-responses-to-immunotherapy-100586520","NCT06916442","Granzyme B-targeted PET Imaging Monitoring Tumor Responses to Immunotherapy","A Single-Arm, Open-Label, Exploratory Study of Granzyme B-Targeted PET Imaging for Evaluating Tumor Response to Immunotherapy in Solid Tumors","GZMB_PET","Inclusion Criteria\n\n1. Voluntarily participate and sign the written informed consent form.\n2. Aged 18 to 90 years (inclusive), regardless of gender.\n3. Treatment-naïve patients with pathologically confirmed malignant solid tumors scheduled to receive immunotherapy.\n4. Willing and able to adhere to scheduled visits, treatment plans, and laboratory tests.\n\nExclusion Criteria\n\n1. Pregnant or lactating patients.\n2. Patients with a known allergy to GZMB-targeted imaging agents or synthetic excipients.\n3. Fasting blood glucose level exceeding 11.0 mmol\u002FL prior to 18F-FDG administration.\n4. Patients unable to undergo PET\u002FCT imaging (e.g., inability to lie supine, claustrophobia, severe anxiety related to radiation exposure).\n5. Patients with poor compliance or other factors deemed by the investigator to preclude participation in the study.",{"count":415,"type":21},"Malignant solid tumors, characterized by their persistently high incidence and mortality rates, pose a significant threat to human health and life, imposing a substantial societal burden. Molecular imaging enables the non-invasive, in vivo visualization of tumorigenesis and progression at the molecular level. Compared to traditional morphology-based imaging techniques, molecular imaging provides more precise information for early tumor diagnosis, treatment efficacy assessment, and clinical disease management. 18F-FDG PET\u002FCT imaging is currently the most widely used molecular imaging modality. However, under immunotherapy, FDG accumulates extensively in activated T cells, leading to increased false-positive evaluations. It fails to effectively distinguish metabolic hyperactivity between proliferative tumor cells (indicative of true progressive disease) and infiltrating immune cells (associated with pseudoprogression), thereby complicating the assessment of immunotherapy efficacy. Therefore, exploring novel molecular imaging probes with high specificity is of critical importance for patients undergoing tumor immunotherapy, as it can lead to more accurate evaluation of treatment efficacy. Granzyme B (GZMB), a serine protease released from cytoplasmic granules of cytotoxic T lymphocytes (CTLs) and natural killer (NK) cells, induces apoptosis in target cells, particularly tumor cells-a central mechanism of tumor immunotherapy. This makes GZMB a promising molecular target for evaluating immunotherapy efficacy. This study aims to assess tumor immunotherapy outcomes using GZMB-targeted PET imaging and compare its performance with 18F-FDG PET\u002FCT. The goal is to achieve timely and accurate efficacy evaluation and longitudinal monitoring, identify potential beneficiaries, optimize clinical decision-making, and ultimately deliver personalized precision treatment to improve overall treatment outcomes.",[133,468,469],"Solid Tumors, Adult","Solid Tumors, Advanced Solid Tumors",[471,472,473,474],"Granzyme B","PET Imaging","Immunotherapy Response","Diagnostic Efficacy","2025-03-31",{"date":477,"type":37},"2025-04-08",{"date":479,"type":21},"2025-04-01",{"date":341,"type":21},{"name":43,"class":44},{"id":483,"slug":484,"hasResults":12,"nctId":485,"briefTitle":486,"officialTitle":486,"acronym":4,"eligibilityCriteria":487,"healthyVolunteers":101,"sex":181,"minAge":303,"maxAge":488,"enrollmentInfo":489,"targetDuration":4,"studyType":55,"phases":4,"briefSummary":491,"conditions":492,"keywords":493,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":497,"lastUpdatePostDateStruct":498,"startDateStruct":500,"completionDateStruct":502,"leadSponsor":504,"locationsCount":45},"100522449","cervical-cancer-screening-with-ngs-hpv-technology-based-on-menstrual-blood-100522449","NCT06082765","Cervical Cancer Screening with NGS-HPV Technology Based on Menstrual Blood","Inclusion Criteria:\n\n1. plan to undergo cervical screening\n2. with regular menstruation (21-35 days)\n3. agree to participate in this study and have signed an informed consent form\n\nExclusion Criteria:\n\n1. with amenorrhea or menopause\n2. suffering from genital tract infection\n3. refuse to participate in this study","60 Years",{"count":490,"type":21},10000,"Our study is a population-based, cross-sectional study. This study is conducted to recruit cervical cancer screening participants to evaluate the application value of using high-throughput sequencing technology to detect HPV in menstrual blood for cervical cancer screening. Our study is designed as a two-phase study :\n\nPhase I : This phase, which will be preparing to recruit 5,000 participants, evaluates the accuracy of menstrual blood (MB) self-sampling for detecting cervical intraepithelial neoplasia grade two or worse (CIN2+) in the general population, with a secondary objective to evaluate the Minipad as a special device to collect MB.\n\nPhase II : This phase, which will continue to recruit toward the 10,000-participant target, will evaluate additional molecular markers (specifically DNA methylation) to optimize alternative triage methods for HPV-positive women in menstrual blood (MB) self-sampling. This phase aims to further reduce unnecessary colposcopies while maintaining high sensitivity for CIN2+ detection.",[187],[494,495,191,496],"HPV","menstrual blood","screening,","2025-02-17",{"date":499,"type":37},"2025-02-18",{"date":501,"type":37},"2021-09-01",{"date":503,"type":21},"2028-03-31",{"name":43,"class":44},{"id":506,"slug":507,"hasResults":12,"nctId":508,"briefTitle":509,"officialTitle":510,"acronym":4,"eligibilityCriteria":511,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":393,"enrollmentInfo":512,"targetDuration":4,"studyType":22,"phases":514,"briefSummary":515,"conditions":516,"keywords":518,"overallStatus":86,"whyStopped":4,"lastUpdateSubmitDate":521,"lastUpdatePostDateStruct":522,"startDateStruct":524,"completionDateStruct":526,"leadSponsor":527,"locationsCount":45},"100575174","the-accuracy-of-targeted-lymph-node-dissection-of-non-small-cell-lung-cancer-patients-according-to-predictive-models-100575174","NCT06768853","The Accuracy of Targeted Lymph Node Dissection of Non-small Cell Lung Cancer Patients According to Predictive Models","Clinical Study on Predicting Mediastinal Lymph Node Metastasis in Patients with Lung Cancer by the Predictive Model Based on Clinical Characteristics and Radiomics","Inclusion Criteria:\n\n1. Age range from 18 to 70 years old;\n2. Chest CT shows a single pulmonary nodule, which may be adenocarcinoma or squamous cell carcinoma;\n3. Chest CT shows multiple pulmonary nodules, but preoperative evaluation suggests that pulmonary nodules other than the main lesion are benign;\n4. Preoperative auxiliary examination evaluates the patient as clinically resectable lung adenocarcinoma or squamous cell carcinoma in stages I, II, or IIIA (UICC-TNM 9th edition);\n5. ECOG score 0-1;\n6. Preoperative lung function FEV1 ≥ 1.0L and actual\u002Fexpected value ≥ 80%;\n7. No contraindications for surgery;\n8. Technically, lobectomy or segmental resection combined with lymph node dissection can be performed;\n9. Preoperative plain scan and enhanced chest CT examination;\n10. The interval between surgery and chest CT, lung function, and electrocardiogram examinations is less than or equal to 28 days;\n11. The patient signs a written informed consent form.\n\nExclusion Criteria:\n\n1. Chest CT suggests multiple primary lung cancer or metastatic cancer;\n2. Previous history of thoracic surgery;\n3. Previous history of malignant tumors;\n4. History of neoadjuvant therapy;\n5. A history of severe heart failure, myocardial infarction, cerebral infarction, and pneumonia within 6 months prior to surgery;\n6. Concurrent active bacterial or fungal infections;\n7. Severe underlying lung diseases such as interstitial lung disease, pulmonary fibrosis, or emphysema are complicated;\n8. Concomitant mental illness;\n9. Pregnant\u002Flactating women.",{"count":513,"type":21},60,[24],"Investigators combined the clinical and radiomics characteristics of resectable non-small cell lung cancer patients to construct an accurate model for preoperative prediction of mediastinal lymph node status. For the patients in the experimental group, lymph nodes will be dissected based on the predicted lymph node status by the model, while in the control group, the lymph nodes will be dissected according to the NCCN guidelines (2023). Investigators expect that performing lymph node dissection according to the predictive model can lead to better prognosis for patients.",[517],"Non-small Cell Lung Cancer",[519,520],"lung cancer","mediastinal lymph node","2025-01-06",{"date":523,"type":37},"2025-01-10",{"date":525,"type":21},"2025-01-01",{"date":246,"type":21},{"name":43,"class":44},{"id":529,"slug":530,"hasResults":12,"nctId":531,"briefTitle":532,"officialTitle":533,"acronym":4,"eligibilityCriteria":534,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":535,"targetDuration":4,"studyType":22,"phases":537,"briefSummary":538,"conditions":539,"keywords":541,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":525,"lastUpdatePostDateStruct":543,"startDateStruct":545,"completionDateStruct":547,"leadSponsor":549,"locationsCount":45},"100574274","early-phase-1-safety-and-efficacy-of-nrg-103-injection-in-the-treatment-of-recurrent-glioblastoma-patients-100574274","NCT06757153","Safety and Efficacy of NRG-103 Injection in the Treatment of Recurrent Glioblastoma Patients","Clinical Study on the Safety and Efficacy of NRG-103 Injection in the Treatment of Recurrent Glioblastoma Patients","Inclusion Criteria:\n\n1. Age≥18 years.\n2. Patients must have histologically or cytologically confirmed glioblastoma(WHO 2021).\n3. Patients have experienced recurrence (RANO 2.0) after previous anti-tumor treatments, including the recurrent tumor has been surgically removed and an Ommaya reservoir has been placed inside the tumor cavity.\n4. The relevant adverse reactions from the previous treatment have been restored to ≤1 level(NCI-CTCAE v5.0).\n5. Karnofsky Performance Score≥70.\n6. Stable doses of dexamethasone during the week prior to inclusion.\n7. Adequate bone marrow reserve: White blood cell count\\>2.0 × 109\u002FL, neutrophil count\\>1.0 × 109\u002FL, platelet count\\>100 × 109\u002FL, international normalized ratio ≤1.5 times ULN, and activated partial thromboplastin time≤1.5 times ULN.\n8. Normal heart, renal and liver function.\n9. Effective method of contraception for patients and their partners.\n10. Written informed consent.\n\nExclusion Criteria:\n\n1. Allergy to the components of the test drug and contrast agent.\n2. Unable to undergo imaging examinations required for the research.\n3. A history of cell therapy, gene therapy, or oncolytic virus therapy.\n4. Undergoing other clinical trials.\n5. A history of anti-tumor vaccines or other immunomodulatory drugs with 4 weeks.\n6. A history of other type of malignant tumors.\n7. Unexplained fever.\n8. A history of autoimmune disease.\n9. A history of immunodeficiency, or other acquired or congenital immunodeficiency diseases, or history of organ transplantation.\n10. Active hepatitis B, or hepatitis C.\n11. Severe heart disease (NYHA III or IV), or poorly controlled diabetes.\n12. Two or more GBM lesions.\n13. GBM lesion located in the brainstem, cerebellum, posterior fossa, or spinal cord, as well as leptomeningeal diseases.\n14. A history of diffuse subarachnoid and subarachnoid diseases.\n15. GBM lesion invades the ventricular wall or tumor cavity communicates with the ventricle after surgery.\n16. A history of encephalitis, multiple sclerosis, or other central nervous system infections.\n17. Cerebral herniation syndrome.\n18. Pregnant and lactating women.\n19. Other situations that the researcher deems unsuitable for entry into the study.",{"count":536,"type":21},15,[126],"The goal of this clinical trial is to learn if NRG103 works to treat recurrent GBM in adults. It will also learn about the safety of NRG103.\n\nThe main questions it aims to answer are:\n\nDoes NRG103 prolong overall survival or disease-free survival in patients with GBM? What medical problems do participants have when receiving NRG103 treatment? Researchers will give patients with NRG103 to see if NRG103 works to treat recurrent GBM.\n\nParticipants will:\n\nReceive NRG103 twice in 14 days Visit the clinic once every 2 weeks for checkups and tests Keep a diary of their symptoms",[540],"Glioblastoma (GBM)",[542],"Glioblastoma;Oncolytic virus;NRG103;Trans-differentiation;",{"date":544,"type":37},"2025-01-03",{"date":546,"type":37},"2024-12-19",{"date":548,"type":21},"2027-12",{"name":43,"class":44},{"id":551,"slug":552,"hasResults":12,"nctId":553,"briefTitle":554,"officialTitle":554,"acronym":4,"eligibilityCriteria":555,"healthyVolunteers":101,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":556,"targetDuration":558,"studyType":55,"phases":4,"briefSummary":559,"conditions":560,"keywords":563,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":566,"lastUpdatePostDateStruct":567,"startDateStruct":569,"completionDateStruct":571,"leadSponsor":573,"locationsCount":574},"100567351","clinical-study-on-the-immune-response-characteristics-of-novel-coronavirus-and-influenza-virus-infection-100567351","NCT06667063","Clinical Study on the Immune Response Characteristics of Novel Coronavirus and Influenza Virus Infection","Inclusion Criteria:\n\n1. volunteers aged 18 years and above at the time of screening;\n2. informed consent obtained from volunteers and volunteers\u002Fwitnesses able to sign the informed consent form;\n3. an interval of ≥3 months from the last COVID-19 or influenza vaccination;\n4. an interval of ≥ 3 months from the last respiratory viral infection such as COVID-19 or Influenza virus occurs; 5.1 cohort 1：novel coronavirus virus antigen-positive and within 48 hours of onset of symptoms of infection; 5.2 cohort 2：influenza virus antigen-positive and within 48 hours of onset of symptoms of infection; 5.3 cohort 3：novel coronavirus and influenza virus antigen-negative, no febrile symptoms, and no symptoms of viral or bacterial respiratory infections.\n\nExclusion Criteria:\n\n1. known or suspected concomitant more serious and medically unstable disease in the judgment of the investigator, including: respiratory disease, tuberculosis, acute infections or active chronic disease, hepatic or renal disease, cardiovascular disease (cardiorespiratory failure), hypertension (systolic blood pressure ≥160 mmHg, diastolic blood pressure ≥100 mmHg), malignant tumors, infectious or allergic skin diseases, and the presence of HIV infection;\n2. Absence of spleen or functional absence of spleen;\n3. immunosuppressive therapy, anti-allergy therapy, cytotoxic therapy, inhaled corticosteroids (excluding corticosteroid spray therapy for allergic rhinitis, and superficial corticosteroid therapy for acute uncomplicated dermatitis) within the past 6 months;\n4. Received blood products within the past 3 months;\n5. has received other vaccines or investigational drugs within the past 1 month;\n6. is receiving anti-tuberculosis treatment;\n7. In the judgment of the investigator, due to a variety of medical, psychological, social, or other conditions that are contrary to the trial protocol or that affect the signing of informed consent by the volunteer.",{"count":557,"type":21},130,"28 Days","This is an open-label, prospective observational study in people 18 years of age and older designed to track changes in the dynamics of the respiratory and peripheral blood immune response in people infected with influenza virus and new coronaviruses, and to resolve the characteristics of the virus-induced natural immune response.",[561,562],"COVID-19","Influenza",[561,562,564,565],"Immune response characteristics","Clinical study","2024-10-30",{"date":568,"type":37},"2024-10-31",{"date":570,"type":37},"2024-09-19",{"date":572,"type":21},"2025-06-30",{"name":43,"class":44},2,{"id":576,"slug":577,"hasResults":12,"nctId":578,"briefTitle":579,"officialTitle":579,"acronym":4,"eligibilityCriteria":580,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":581,"targetDuration":4,"studyType":22,"phases":583,"briefSummary":584,"conditions":585,"keywords":588,"overallStatus":86,"whyStopped":4,"lastUpdateSubmitDate":593,"lastUpdatePostDateStruct":594,"startDateStruct":596,"completionDateStruct":598,"leadSponsor":600,"locationsCount":45},"100553690","efficacy-of-semi-rigid-ureteroscopic-laser-lithotripsy-in-the-treatment-of-proximal-ureteral-stones-a-randomized-controlled-trial-100553690","NCT06489366","Efficacy of Semi-rigid Ureteroscopic Laser Lithotripsy in the Treatment of Proximal Ureteral Stones: a Randomized Controlled Trial","Inclusion Criteria:\n\n1. ≥18 years old;\n2. patients diagnosed with unilateral proximal ureteral stones ≤2cm by computed tomography (CT)\u002FKidney and upper bladder (KUB) radiography who required surgery;\n3. patients who volunteered to participate in this study.\n\nExclusion Criteria:\n\n1. Unable to give informed consent;\n2. Untreated urinary tract infection;\n3. Pregnant women;\n4. Known anatomical abnormalities (such as urinary diversion or ureteral stenosis);\n5. Urothelial tumors, transplanted kidney stones, irreversible coagulopathy;\n6. The semi-rigid ureteroscope cannot reach the stone site, ureteroscopy-negative stones, and stones can be removed directly without laser lithotripsy;\n7. The researchers believe that they are not suitable for participation in this study.",{"count":582,"type":21},138,[24],"The efficacy of Ho: YAG and TFL combined with semirigid ureteroscopic treatment of proximal ureteral stones will be compared.",[586,587],"Urolithiasis","Proximal Ureteral Stone",[589,590,591,592],"Proximal ureteral stones","Ho: YAG lithotripsy","Thulium Fiber laser (TFL) lithotripsy","Semirigid ureteroscopic lithotripsy","2024-06-28",{"date":595,"type":37},"2024-07-05",{"date":597,"type":21},"2024-06-26",{"date":599,"type":21},"2025-02-26",{"name":43,"class":44},{"id":602,"slug":603,"hasResults":12,"nctId":604,"briefTitle":605,"officialTitle":606,"acronym":4,"eligibilityCriteria":607,"healthyVolunteers":12,"sex":181,"minAge":18,"maxAge":74,"enrollmentInfo":608,"targetDuration":4,"studyType":22,"phases":610,"briefSummary":611,"conditions":612,"keywords":613,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":618,"lastUpdatePostDateStruct":619,"startDateStruct":621,"completionDateStruct":623,"leadSponsor":625,"locationsCount":45},"100502050","phase-2-cadonilimab-plus-anlotinib-for-rmp-cervical-cancer-100502050","NCT05817214","Cadonilimab Plus Anlotinib for R\u002FM\u002FP Cervical Cancer","Cadonilimab Plus Anlotinib for Recurrent, Metastasis or Persistent Cervical Cancer","Inclusion Criteria:\n\n1. Obtain informed consent signed by the patient or their legal representative;\n2. Female patients aged ≥18 and ≤75 years old;\n3. ECOG PS score of 0-1;\n4. Expected survival period ≥6 months;\n5. Pathological types include squamous cell carcinoma, adenocarcinoma, or adenosquamous carcinoma originating from the cervix;\n6. Can provide tumor tissue specimens archived within 2 years or willing to undergo tumor tissue biopsy to provide fresh specimens for further testing;\n7. At least one evaluable lesion meeting the criteria of RECIST 1.1;\n8. Have only received standard first-line systemic treatment in the past: (1) If first-line treatment does not include immunotherapy, failure of first-line treatment is sufficient (for patients who have previously achieved cure, any number of neoadjuvant or adjuvant chemotherapy cycles do not count towards the line count, unless disease progression occurs within 3 months after ≥3 cycles of neoadjuvant\u002Fadjuvant chemotherapy; for persistent disease, ≥2 cycles of previous chemotherapy can be counted as one line, otherwise not counted); (2) If first-line treatment includes immunotherapy, clinical benefit must occur after first-line treatment, namely partial or complete tumor remission, with the duration of efficacy lasting more than 6 months.\n9. Sitting blood pressure in a resting state is below the normal high value (\\\u003C140\u002F90 mmHg), or 24-hour dynamic blood pressure monitoring average blood pressure is below the normal high value (\\\u003C140\u002F90 mmHg), regardless of whether antihypertensive drugs are being taken orally;\n10. Hematological indicators meet the following criteria (not transfused or administered hematopoietic growth factor drugs within the past 7 days): white blood cell count (WBC) ≥3.5×109\u002FL, absolute neutrophil count (ANC) ≥1.5×109\u002FL, platelets (PLT) ≥100×109\u002FL, hemoglobin (Hb) ≥90g\u002FL;\n11. Liver function indicators meet the following criteria: ALT and AST ≤2.5 times the upper limit of normal (ULN), bilirubin ≤1.5×ULN, albumin ≥35g\u002FL;\n12. Coagulation function indicators meet the following criteria (not receiving anticoagulant or hemostatic drug therapy): PT and APTT ≤1.5×ULN, while INR ≤1.5 ULN;\n13. Renal function indicators meet the following criteria: blood urea nitrogen (BUN) and creatinine (Cr) ≤1.5×ULN, urinary protein \\\u003C2+ or 24-hour urinary protein quantification \\\u003C1g;\n14. Women of childbearing age must undergo serum pregnancy testing within 7 days before initial medication, with negative results, and not be lactating. Female subjects of childbearing age must agree to use effective contraception during the study period and within 180 days after the last dose of the study drug;\n15. Good compliance.\n\nExclusion Criteria:\n\nTranslation:\n\n1. Any unstable systemic diseases, including but not limited to active infections within 4 weeks (defined as fever exceeding 38.5°C, evidence of bacteremia, or evidence of infectious changes in the heart, brain, kidneys, lungs, liver, and intestines), circulatory accidents within 6 months (malignant hypertensive crisis, myocardial infarction, severe\u002Funstable angina, heart failure above NYHA class 2, clinically significant supraventricular or ventricular arrhythmias, or cerebral vascular accidents not yet recovered from or resulting in severe sequelae), uncontrolled type 2 diabetes (fasting blood glucose \\>11.1 mmol\u002FL or glycated hemoglobin \\>8%), and pulmonary insufficiency (any cause leading to decreased lung function, defined as FEV1\u002FFVC \\\u003C70%, FEV1 \\\u003C80% of predicted value).\n2. History of autoimmune diseases, including but not limited to systemic lupus erythematosus, rheumatoid arthritis, autoimmune liver diseases, systemic vasculitis, scleroderma, dermatomyositis, autoimmune hemolytic anemia;\n3. Human immunodeficiency virus (HIV) infection or known acquired immunodeficiency syndrome (AIDS); active hepatitis (hepatitis B, defined as HBV-DNA ≥ 500 IU\u002Fml; hepatitis C, defined as HCV-RNA higher than the detection limit of the assay) or combined hepatitis B and hepatitis C infection;\n4. History of attenuated live vaccine administration within 28 days before the first dose of the study drug or expected attenuated live vaccine administration during the study period;\n5. Tumor invasion of major blood vessels on imaging or investigator judgment indicating a high risk of tumor invasion of important vessels causing fatal bleeding or other diseases with a high risk of severe bleeding;\n6. Previous treatment with anlotinib or cadonilimab;\n7. Evidence of active tuberculosis infection within the past year before screening;\n8. Diagnosis of any other malignant tumors, adequately treated basal cell carcinoma or squamous cell skin carcinoma, or cervical carcinoma in situ within 5 years before entering the study;\n9. Major surgery within 28 days before randomization (tissue biopsy for diagnostic purposes and insertion of a central venous catheter via percutaneous puncture are allowed);\n10. Active venous or arterial thromboembolic events within 6 months before randomization, such as cerebrovascular accidents (including transient ischemic attacks), deep vein thrombosis, and pulmonary embolism;\n11. Previous or planned allogeneic bone marrow or solid organ transplantation;\n12. Clinically significant intestinal obstruction, occurrence of intestinal repair, intestinal anastomosis, intestinal diversion, or enterocutaneous fistula for any reason at any time;\n13. Participants who experienced symptoms of hemoptysis within 2 months before entering the study and had a maximum daily hemoptysis volume of approximately ≥2.5 mL. Participants who experienced significant bleeding symptoms or had a clear bleeding tendency, such as gastrointestinal bleeding, bleeding gastric ulcers, baseline fecal occult blood test ++ and above, or vasculitis, within 3 months before entering the study; known hereditary or acquired bleeding and thrombotic tendencies, such as hemophilia, coagulation disorders, thrombocytopenia, splenic hyperfunction, etc.;\n14. Visible hematuria or other evidence of active urinary system bleeding;\n15. Currently receiving thrombolysis or requiring long-term anticoagulant therapy with warfarin or heparin, or requiring long-term antiplatelet therapy (aspirin ≥300 mg\u002Fday or clopidogrel ≥75 mg\u002Fday);\n16. Known allergy to anlotinib, cadonilimab or any of their excipients;\n17. Participation in any other drug clinical studies within the previous 4 weeks before randomization or within 5 half-lives of the last study drug administration;\n18. History of substance abuse, alcoholism, or drug addiction;\n19. Coexisting severe cognitive impairment and inability to achieve stable mental status;\n20. As judged by the investigator, patients may have other factors that could lead to premature termination of the study, such as other serious illnesses or severe laboratory abnormalities, or factors affecting the safety of the participants or the collection of trial data and samples due to family or social reasons, etc.",{"count":609,"type":21},35,[78],"The goal of this clinical trial is to test a new treatment combination including cadonilimab, anlotinib and granulocyte-macrophage colony-stimulating factor (GM-CSF) in recurrent, metastasis and persistent cervical cancer. The main questions it aims to answer are:\n\n* The efficacy of this combination in R\u002FM\u002FP CC;\n* The tolerance of this combination in R\u002FM\u002FP CC;\n* Possible biomarker of treatment response for this combination.\n\nParticipants will receive cadonilimab of 10mg\u002Fkg every three weeks at day 1, take anlotinib (12mg) orally in day 1 to day 14, then take a 7 days break and subcutaneously injection of GM-CSF (200ug) from day 1 to day 14, then also take a 7-days break. This treatment will continue until progression or intolerable toxicity or withdraw of participants and it will last for no longer than 2 years.",[187],[187,614,615,616,617],"Cadonilimab","Anlotinib","Granulocyte-macrophage colony-stimulating factor","Immunotherapy","2024-04-18",{"date":620,"type":37},"2024-04-19",{"date":622,"type":37},"2023-02-16",{"date":624,"type":21},"2027-02-28",{"name":43,"class":44},""]